Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.49
- Piotroski Score 6.00
- Grade Overweight
- Symbol (MNKD)
- Company MannKind Corporation
- Price $6.90
- Changes Percentage (0.22%)
- Change $0.02
- Day Low $6.74
- Day High $6.98
- Year High $7.63
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $11.00
- High Stock Price Target $12.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.04
- Trailing P/E Ratio 116.75
- Forward P/E Ratio 116.75
- P/E Growth 116.75
- Net Income $-11,938,000
Income Statement
Quarterly
Annual
Latest News of MNKD
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
MannKind (MNKD) Q3 2024 Earnings Call Transcript
The Motley Fool Stock Advisor team identified the 10 best stocks for investors, excluding MannKind. MannKind is focusing on developing innovative treatments for diseases like NTM lung disease and IPF....
By Yahoo! Finance | 2 weeks ago -
MannKind Corporation (MNKD): Short Seller Sentiment is Bearish
Insider Monkey analyzed the 14 worst 52-week high stocks to buy according to short sellers, focusing on MannKind Corporation (NASDAQ:MNKD). With the US Federal Reserve's rate cuts, the economy faces c...
By Yahoo! Finance | 2 months ago -
MannKind Corporation (MNKD): Short Seller Sentiment is Bearish on This Cancer Stock
A compilation of the 10 worst cancer stocks according to short sellers includes MannKind Corporation (NASDAQ:MNKD). The global cancer burden is rising, with the oncology market projected to surpass $5...
By Yahoo! Finance | 2 months ago
